Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned a consensus rating of “Buy” from the eleven analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $47.5714.

A number of analysts have recently issued reports on IMUX shares. Lifesci Capital raised shares of Immunic to a “strong-buy” rating in a research note on Monday, May 4th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. D. Boral Capital cut Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. Stifel Nicolaus set a $25.00 price objective on Immunic and gave the company a “buy” rating in a research report on Thursday, April 16th. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Immunic in a research note on Thursday, May 14th.

Institutional Investors Weigh In On Immunic

Institutional investors have recently added to or reduced their stakes in the stock. CTC Alternative Strategies Ltd. bought a new stake in shares of Immunic during the first quarter valued at approximately $27,000. ADAR1 Capital Management LLC bought a new stake in shares of Immunic during the first quarter valued at approximately $33,000. Qube Research & Technologies Ltd bought a new position in shares of Immunic during the third quarter worth $29,000. Two Sigma Investments LP bought a new position in shares of Immunic during the third quarter worth $52,000. Finally, Virtu Financial LLC bought a new position in shares of Immunic during the third quarter worth $99,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Trading Down 11.5%

Shares of IMUX stock opened at $12.77 on Friday. Immunic has a 12 month low of $5.06 and a 12 month high of $15.77. The stock has a market cap of $173.93 million, a P/E ratio of -2.29 and a beta of 1.37. The company has a 50 day simple moving average of $11.78 and a two-hundred day simple moving average of $9.25.

Immunic (NASDAQ:IMUX) last announced its earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37). As a group, equities analysts forecast that Immunic will post -4.57 earnings per share for the current year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.